Knockout Mouse Catalog | Cyagen APAC

Everyone feels sad sometimes. When you're sadder than usual, you might say you're feeling "depressed." However, if the sadness or bad mood persists for weeks (or longer) and you experience other changes in behavior, it could be signs of clinical depression, also known as major depressive disorder (MDD).

In recent years, the incidence of depression has increased, but we still know little about its etiology and pathogenesis. Establishing a suitable animal model will help us deeply explore the pathogenesis of MDD and find effective treatments. Herein, we introduce MDD and its related mouse models to help further our understanding of this increasingly common mental disorder in modern society.

 

What is Major Depressive Disorder?

Major depressive disorder (MDD), also known as clinical depression, is characterized by significant and persistent depressed mood as the main clinical symptom, and is the most common type of mood disorder. The clinical symptoms of MDD include feelings of hopelessness and/or guilt,, loss of interest and happiness, significant weight changes, social avoidance, sleep disturbance, tiredness, and more; in more severe cases, some MDD patients experience severe anxiety symptoms, suicidal ideation and behavior.[1]

The most common time of onset is in a person's 20s,[2][3] with females affected about twice as often as males.[3] The course of the disorder varies widely, from a singular episode lasting months, to a lifelong disorder with recurrent major depressive episodes.

MDD is believed to be caused by a combination of genetic, environmental, and psychological factors,[4] with about 40% of the risk being genetic.[5] Risk factors include a family history of the condition, major life changes, certain medications, chronic health problems, and substance use disorders.[4][5] MDD can negatively affect the patient's personal life, work, or education, and cause issues with sleeping habits, eating habits, and general health.[4][5] In 2017, MDD affected approximately 163 million people (2% of the world's population).[6] The percentage of people who are affected at one point in their life varies worldwide, from as low as 7% in Japan up to 21% in France. Lifetime rates are higher in the developed world (15%) compared to the developing world (11%).[3] The disorder causes the second-highest disability-adjusted life-years following lower back pain.[7]

Depression isn't just a bout of melancholy, it's not a weakness that you can't simply "snap out" of, but is caused by a chemical imbalance in the neurotransmitters of the brain. Those with MDD are typically treated with psychotherapy and antidepressant medication.[4] Medication appears to be effective, but the effect may be significant only in the most severely depressed.[8][9] Hospitalization (which may be involuntary) may be necessary in cases with associated self-neglect or a significant risk of harm to self or others. Electroconvulsive therapy (ECT) may be considered if other measures are not effective.[4]

 

Animal Models of Major Depressive Disorder

There is increasing evidence that MDD is a disease caused by the interaction of multiple complex factors such as genetics and environment.[10] Scientists have developed animal models that reproduce typical symptoms of MDD in humans and can help us better understand the pathogenesis of the disease. Commonly used modeling methods for rodents with MDD include: stress modeling, surgical modeling, drug modeling, and genetic modeling [11].

 

Figure 1. Animal models of depression.[12]

 

Stress modeling

Studies have shown that acute or chronic stress can lead to mental disorders such as depression. Specific modeling methods include imposing uncontrollable and unpredictable stressors on rodents, which can be divided into acute stress models and chronic stress models.

Learned helplessness (LH) model

Modeling method: Subjecting experimental animals to constant, unavoidable electric foot shocks; the animals can not learn to avoid the shocks, is known as learned helplessness (LH).

Phenotypic features: Depression-like behaviors such as weight loss, altered motor activity, sleep disturbance, decreased motivated behavior, and anhedonia can be observed. Although it has not yet been proven whether learned helplessness is a unique symptom of MDD patients,  this model is commonly used for preliminary screening of antidepressant drugs.

Chronic social defeat stress (CSDS) model

Modeling method: Experimental animals are placed in cages with aggressive resident mice (such as ICR mice) and subjected to long-term physical and psychological stress. Susceptible animals exhibit negative states and depressed moods due to repeated aggression, corresponding to depression-like behaviors such as social avoidance and anhedonia.

Phenotypic features: A large number of animals is required, resulting in the consumption of experimental facilities and human resources; since female animals are less aggressive and difficult to achieve social defeat, this modeling method is only suitable for male rodents.

Chronic restraint stress (CRS) model

Modeling method: Place the animal in a restraint tube immobilized (well-ventilated) for 2-8 hours per day for 14-21 days.

Phenotypic features: The advantage of this model is that the modeling method is simple, and it can show depression-like phenotypes such as reduced social interaction, anhedonia, and impaired spatial learning and memory, which are highly similar to symptoms of MDD in humans. However, its disadvantage is that animals are prone to adapt to repeated restraint stress, making it difficult to maintain depression-like symptoms.

Chronic unpredictable mild stress (CUMS) model

Since a single repetitive stress can easily trigger an adaptive response in animals, using a chronic unpredictable mild stress model can avoid this situation and lead to long-term effective depression-like behaviors.

Modeling method: Experimental animals are exposed to various unpredictable mild stressors over a period of time (2–4 weeks), including circadian rhythm changes, cage tilting, social pressure, hot and cold stimulation, restraint, tail suspension, etc.

Phenotypic features: This model shows a persistent depression state, which better simulates the human response caused by long-term exposure to various mild stressors in society, and is highly similar to symptoms of MDD in humans. Therefore, it is currently considered to be the most classic animal model of depression. However, its disadvantage lies in the time-consuming and heavy workload of model development.

Surgical modeling: Olfactory bulbectomy

Olfactory bulbectomy (OBX), the most commonly used surgical modeling method, relies on bilateral surgical ablation of the olfactory bulbs in rodents. Two weeks later, rodents display hyperactive behaviors when placed in a novel environment as well as increased sensitivity to stress, disrupted sleep-wake cycles and weight loss, transient anhedonia, and despair, similar to that observed in MDD patients.

This model has good stability, but its disadvantages are that it is only a reference for a certain number of MDD patients because it is produced by olfactory bulb cortex damage and the animal mortality rate is high during the modeling process.

Drug modeling

The administration of drugs can induce similar phenotypes as those in depression, but this modeling method usually comes with a number of undesirable side effects.

Corticosterone administration

Chronic corticosterone administration can be given to experimental animals by subcutaneous injection or by exposing them to high levels of glucocorticoids in daily drinking water. After weeks to months, rodents can develop despaired behavior, anhedonia, impaired learning and memory, and anxiety-like behaviors.

This modeling method has the advantages of simplicity and a short production cycle, but there are certain side effects. Additionally, while there are concerns that the method may impair positive valence behaviors associated with reward processing, it remains a useful experimental model for preclinical study of stress-induced mood disorders.

Reserpine administration

Reserpine, a vesicle reuptake inhibitor, induces a depression-like phenotype in animals when administered intravenously.

The reserpine administration model has the advantages of fast and simple modeling, and depression-like behavior can appear as soon as 1 hour after intravenous injection. However, the administration of reserpine can produce symptoms similar to Parkinson's disease, such as dyskinesia and hypothermia, resulting in high mortality of experimental animals.

Genetic modeling

Depression is closely related to genetics. Therefore, many studies have tried to modify the expression of genes associated with vulnerability to developing MDD. Many transgenic lines have been created targeting genes implicated in the serotoninergic and noradrenergic systems, and HPA axis regulation.

Genetic models based on the 5-HT system

5-hydroxytryptamine (5-HT) targeted drugs are commonly used to treat depression, so most genetic models of MDD are based on the 5-HT neuromodulatory system.

▶ Tph1/Tph2: Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in the synthesis of 5-HT, and its two subtypes, TPH1 and TPH2, are involved in catalyzing the 5-HT system. Tph2-/- mice show increased immobility time in the tail suspension test, suggesting that this model develops a depression-like phenotype of despair behavior and has higher levels of anxiety. In addition, the corresponding depression-like behavior was also shown in the Tph1/Tph2 double knockout mouse model.

▶ Vmat1/Vmat2: The vesicular monoamine transporter (VMAT) consists of two proteins: VMAT1 and VMAT2. VMAT1 is enriched in chromogranin, whereas VMAT is mainly expressed in monoaminergic neurons. Vmat2-/- mice exhibit homozygous lethality, while Vmat2+/- mice show obvious depression-like phenotypes, such as despair behavior and anhedonia, but no anxiety-like behavior was observed.

BDNF-based genetic models

BDNF is the most studied gene for depression. However, homozygous genetic model mice lacking Bdnf did not survive, while the phenotype of heterozygous Bdnf knockout (KO) mice was not different from that of normal animals.

Genetic models based on the HPA axis

Genetic manipulation of the HPA axis to alter MDD-associated genes provides an excellent opportunity to explore the molecular basis of MDD. For example, overexpression of corticotropin-releasing factor (CRF) in mice resulted in increased anxiety-like behavior, but not depression-like behavior. Homozygous CRF knockout (KO) mice showed no behavioral abnormalities compared with controls.

In summation, MDD is a multifactorial disease that is caused by multiple genes and environmental factors, so a single gene deletion or overexpression cannot reproduce all the core symptoms of depression. In addition, due to the high cost of modeling, such gene editing models are limited in clinical application.

 

Cyagen’s Mice Accelerate Your Research on MDD

For mental illnesses like MDD, Cyagen can establish acute and chronic stress models through behavioral methods. Moreover, Cyagen Knockout Catalog Models also provides researchers with KO & conditional (cKO) mouse strains of MDD-related genes. Click the links in Table 1 below to view the corresponding product information and strain description!

 

Gene Name

Technical Type

Details

Bdnf

KO

Click here

cKO

Click here

Comt

KO

Click here

cKO

Click here

Gnb3

KO

Click here

cKO

Click here

Htr1a

KO

Click here

cKO

Click here

Htr1b

KO

Click here

cKO

Click here

Htr2a

KO

Click here

cKO

Click here

Htr2c

KO

Click here

cKO

Click here

Maoa

KO

Click here

cKO

Click here

Slc6a2

KO

Click here

cKO

Click here

Slc6a3

KO

Click here

cKO

Click here

Slc6a4

KO

Click here

cKO

Click here

Tph1

KO

Click here

cKO

Click here

Table 1. List of Cyagen’s KO/cKO mice

 

Looking for animal model supporting services? Cyagen provides detection services for various depressive phenotypes in rats and mice through comprehensive behavioral methods, such as sucrose preference test, tail suspension test, forced swimming test, and more.

Please contact us so that our Model Design Specialists may promptly project needs. Alternatively, you can always email service-apac@cyagen.com to inquire about our services or obtain a quote for your project.

 

 

References:

[1] Hasin D.S., Sarvet A.L., Meyers J.L., Saha T.D., Ruan W.J., Stohl M., Grant B.F. Epidemiology of adult dsm-5 major depressive disorder and its specifiers in the united states. JAMA Psychiatry. 2018;75:336–346. doi: 10.1001/jamapsychiatry.2017.4602.

[2] American Psychiatric Association 2013, p. 165.

[3] Kessler RC, Bromet EJ (2013). "The epidemiology of depression across cultures". Annual Review of Public Health. 34: 119–38. doi:10.1146/annurev-publhealth-031912-114409. PMC 4100461. PMID 23514317.

[4] "Depression". U.S. National Institute of Mental Health (NIMH). May 2016. Archived from the original on 5 August 2016. Retrieved 31 July 2016.

[5] American Psychiatric Association 2013, p. 166.

[6] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (10 November 2018). "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017". Lancet. 392 (10159): 1789–1858. doi:10.1016/S0140-6736(18)32279-7. PMC 6227754. PMID 30496104.

[7] Global Burden of Disease Study 2013 Collaborators (August 2015). "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 386 (9995): 743–800. doi:10.1016/S0140-6736(15)60692-4. PMC 4561509. PMID 26063472.

[8] Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J (January 2010). "Antidepressant drug effects and depression severity: a patient-level meta-analysis". JAMA. 303 (1): 47–53. doi:10.1001/jama.2009.1943. PMC 3712503. PMID 20051569.

[9] Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (February 2008). "Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration". PLOS Medicine. 5 (2): e45. doi:10.1371/journal.pmed.0050045. PMC 2253608. PMID 18303940.

[10] Wang Q, Timberlake MA 2nd, Prall K, Dwivedi Y. The recent progress in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2017;77:99-109.

[11] Becker M, Pinhasov A, Ornoy A. Animal Models of Depression: What Can They Teach Us about the Human Disease?. Diagnostics (Basel). 2021;11(1):123. Published 2021 Jan 14. doi:10.3390/diagnostics11010123

[12] Planchez B, Surget A, Belzung C. Animal models of major depression: drawbacks and challenges. J Neural Transm (Vienna). 2019 Nov;126(11):1383-1408. doi: 10.1007/s00702-019-02084-y. Epub 2019 Oct 4. PMID: 31584111; PMCID: PMC6815270.

  • Contact Us

    We will respond to you in 1-2 business days.

    *

    The username is required

    *

    The user's email is required

    Please enter a valid email address.

    *

    The content is required

    *